Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026

Thursday, October 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Emergent BioSolutions Inc. will hold a conference call on November 2, 2026, to discuss its financial results for the third quarter of 2026. The call is scheduled for 5:00 p.m. eastern time and will be accessible via webcast. Participants can pre-register for the call to receive further details.

Market Sentiment Analysis

POSITIVE FACTORS

  • Emergent BioSolutions is actively engaging with investors.
  • The scheduled conference call indicates transparency in financial reporting.
  • The event is set to provide insights into the company's performance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
COVID-HIG
Phase 1 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the third quarter of 2026. Participants can access the conference call via webcast and also by visiting the Investors page of Emergent’s website. Participants can pre-register for the teleconference at the following link and will receive an email with a calendar reminder, dial-in number and a unique cod

Frequently Asked Questions

When will Emergent BioSolutions report its Q3 2026 results?

Emergent BioSolutions will report its Q3 2026 results on November 2, 2026.

What time is the conference call for Q3 2026 results?

The conference call is scheduled for 5:00 p.m. eastern time.

How can participants access the conference call?

Participants can access the call via webcast or the Investors page of Emergent's website.

Is pre-registration required for the conference call?

Participants can pre-register for the teleconference to receive details.

ShareAdd on Google
Tags: EBS Emergent BioSolutions financial results Q3 2026 conference call
Last updated: Oct 15, 2026

Biotech snapshot

Cash runway
$140M liquidity · $0M/mo burn
Low dilution risk
Lead asset
COVID-HIGPhase 1
SARS-CoV-2 Infection →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →